Can PCE Induction Improve Outcomes in Advanced HNSCC?
Definitive chemoradiotherapy (CRT) is a standard approach for locally advanced head and neck squamous cell carcinoma (HNSCC). In Stage IV disease, however, distant metastasis and early recurrence hold 5-year survival to roughly 50 to 60%. And so induction chemotherapy has long been proposed as a way to shrink tumors and treat micrometastases early.
The best-studied regimen—docetaxel, cisplatin, and 5-fluorouracil (TPF) —has a demanding toxicity profile: Grade 3 to 4 neutropenia occurs in 60 to 80% of patients. Iijima and colleagues at Tokai University in Japan asked whether a safer induction regimen could add disease control without undermining the CRT that follows.
Evaluating PCE Induction Before Chemoradiotherapy
Investigators at Tokai University Hospital retrospectively analyzed 128 patients with stage IVA or IVB HNSCC without distant metastases who received treatment between January 2017 and December 2024. Survival analyses included 127 patients who initiated CRT, with follow-up measured from CRT initiation to reduce immortal time bias.
Patients received either two cycles of the paclitaxel, carboplatin, and cetuximab (PCE) regimen followed by definitive CRT (n=52) or CRT alone (n=76) with concurrent cisplatin.
Treatment Response and Completion Rates
Notably, patients receiving PCE had more advanced disease at baseline, including higher proportions of T3–T4 tumors (90.4% vs 65.8%; p = 0.001) and stage IVB disease (34.6% vs 15.8%; p = 0.014).
Despite this, induction went smoothly:
- The overall response rate after PCE induction was 82.7%.
- Every patient who started CRT completed it.
- A cumulative cisplatin dose of at least 200 mg/m² was reached more often with PCE (86.5% vs. 59.2%; p = 0.002).
During PCE induction, Grade 3 or higher adverse events—mostly neutropenia—occurred in 11.5% of PCE patients, and there were no grade 4 or 5 events. Alopecia and acneiform rash were common but generally low grade. One patient died suddenly of cardiac causes after induction but before starting CRT.
Survival Outcomes Suggest a Potential Benefit
Two-year progression-free survival (PFS) was 74.1% with PCE induction versus 49.4% with CRT alone. PCE was associated with significantly longer PFS in both unadjusted (hazard ratio [HR]=0.515; p = 0.043) and adjusted analyses accounting for T classification and Stage (HR, 0.477; p = 0.028).
However, overall survival (OS) did not differ significantly (adjusted HR, 0.553; p = 0.147). Two-year OS was 75.6% versus 66.6%.
An exploratory analysis of patients with sinonasal cancer suggested higher two-year PFS with PCE (90.9% vs 42.9%; p = 0.044) and improved OS (88.9% vs 42.9%; p = 0.145), although the small subgroup limits interpretation.
Clinical Implications
Although these findings suggest that PCE induction is feasible, several limitations warrant consideration. The retrospective, nonrandomized design introduces potential selection bias, while median follow-up was substantially shorter with PCE than CRT alone (17 vs 65 months). Additionally, the study did not directly compare PCE with TPF or comprehensively assess comparative toxicity during CRT.
Overall, PCE induction was associated with high treatment completion and longer PFS, but a definitive survival benefit remains unproven. Larger prospective randomized studies are needed to establish whether PCE offers a meaningful alternative to existing induction regimens.
Reference:
Iijima H, Sakai A, Yamauchi M, et al. Paclitaxel, carboplatin, and cetuximab induction chemotherapy for locally advanced head and neck squamous cell carcinoma: A retrospective evaluation of treatment outcomes and safety. Curr Ther Res Clin Exp. 2026;105:100843. doi:10.1016/j.curtheres.2026.100843
